Mitral Valve Surgery after Edge-to-Edge Repair

In last few years, transcatheter edge-to-edge repair (TEER) with MitraClip has been shown safe and effective, both for primary and secondary mitral valve regurgitation (MR), given the increasing interventionist and echocardiographer experience.    However, there is a group of patients that require surgery after failed TEER, either because of bad evolution or because device implantation is not feasible.  

Cirugía valvular mitral post tratamiento borde a borde

At present, there are no large studies on this population, and we do not know the impact of this etiology, be it primary or secondary, on outcomes.  In addition, there are no data on evolution after surgery.

The study looked at the CUTTING-EDGE Registry from 2009 to 2020, including 330 patients undergoing surgery after edge-to-edge repair. 155 (47%) had primary MR and 175 secondary MR. 

Inclusion criteria were: residual or significant MR, significant mitral stenosis, leaflet lesion, endocarditis, device detachment, device embolization or non-viable implantation.  

Mean age was 73 and 42% were women. 10.3% presented prior stroke, 15.8% peripheral vascular disease, 35.5% COPD, 4.2% dialysis, 56% pulmonary hypertension, 58.5% atrial fibrillation, and 26% prior cardiovascular surgery. STS was 4%. Most belonged in functional class III-IV.

Leia também: Provisional Stenting vs. Culotte: 5-Year Results of EBC TWO.

Secondary MR patients presented more CAD, diabetes, kidney function deterioration (41.3% vs. 62.3% p<0.0001 and pacemaker implantation.

Left ventricular ejection fraction was lower among secondary MR patients (41.1% vs 55.6% p<0.001).

Mean time from TEER to surgery time was 3.5 months and mostly because of: 33.6% recurrent MR, 28.8% residual MR, in; 25.2% loss of device insertion, 21.1% partial detachment, 14.5% mitral stenosis and 2.1% embolization. Mitral stenosis was more frequent among secondary MR patients (19.4% vs. 9% p=0.008).

In-hospital and 30-day mortality was 15.2% among primary MR patients and 16.7% in secondary MR patients. At 30 days there was a tendency towards higher mortality among secondary MR patients (20.4% vs. 12.7% p=0.07). There was no difference in hospital stay (13 days) or repeat hospitalization (6.2%), neither were there differences in hospital complications. 

Leia também: Impact of Right Ventricular Pacing in Patients with Permanent Pacemaker Implantation after TAVR.

At one year, global mortality was 31.3% global, and it was higher among secondary MR patients (38.3% vs. 23.2% p=0.01).

Actuarial cumulative survival rate after mitral valve surgery was 75.9% at one year and 68.3% at 3 years, and it was lower in secondary MR patients.

Mortality predictors at one year were: kidney failure, pre-operatory MR, emergency surgery, male sex, cirrhosis, tricuspid failure, and time off-pump.

Conclusion

Surgical risk after failed TEER is no trivial matter, seeing as it involves higher mortality, especially for patients with secondary MR. These findings provide valuable information for future research aiming at improving evolution. 

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of Mitral Regurgitation Etiology on Mitral Surgery After Transcatheter Edge-to-Edge Repair. From de CUTTING-EDGE Registry.

Reference: Zaid, et al. J Am Coll Caridoll Intv 2023;16:1176-1188.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...